登录 注册 会员服务 联系我们

Non-curative resection for surgical T4b esophageal cancer: esophagectomy or non-esophagectomy?

  • Published:2023-05-20 Issue:1 Volume:408 Page:
  • ISSN:1435-2451
  • Container-title:Langenbeck's Archives of Surgery
  • language:en
  • Short-container-title:Langenbecks Arch Surg

Author:

Fujii Yusuke,Daiko Hiroyuki,Kubo Kentaro,Kanematsu Kyohei,Utsunomiya Daichi,Kurita Daisuke,Ishiyama Koshiro,Oguma Junya

Publisher

Springer Science and Business Media LLC

Subject

Surgery

Reference16 articles.

1. Ohtsu A, Boku N, Muro K, Chin K, Muto M, Yoshida S, Satake M, Ishikura S, Ogino T, Miyata Y, Seki S, Kaneko K, Nakamura A (1999) Definitive chemoradiotherapy for T4 and/or M1 lymph node squamous cell carcinoma of the esophagus. J Clin Oncol 17:2915–2921. https://doi.org/10.1200/JCO.1999.17.9.2915

2. Cushman TR, Shaaban SG, Moreno AC, Lin C, Verma V (2019) Management of unresectable T4b esophageal cancer: practice patterns and outcomes from the national cancer data base. Am J Clin Oncol 42:154–159. https://doi.org/10.1097/COC.0000000000000499

3. Miyata H, Yamasaki M, Takiguchi S, Nakajima K, Fujiwara Y, Nishida T, Mori M, Doki Y (2009) Salvage esophagectomy after definitive chemoradiotherapy for thoracic esophageal cancer. J Surg Oncol 100:442–446. https://doi.org/10.1002/jso.21353

4. Makino T, Yamasaki M, Miyazaki Y, Wada N, Takahashi T, Kurokawa Y, Nakajima K, Takiguchi S, Mori M, Doki Y (2018) Utility of initial induction chemotherapy with 5-fluorouracil, cisplatin, and docetaxel (DCF) for T4 esophageal cancer: a propensity score-matched analysis. Dis Esophagus. 31. https://doi.org/10.1093/dote/dox130

5. Terada M, Hara H, Daiko H, Mizusawa J, Kadota T, Hori K, Ogawa H, Ogata T, Sakanaka K, Sakamoto T, Kato K, Kitagawa Y (2019) Phase III study of tri-modality combination therapy with induction docetaxel plus cisplatin and 5-fluorouracil versus definitive chemoradiotherapy for locally advanced unresectable squamous-cell carcinoma of the thoracic esophagus (JCOG1510: TRIANgLE). Jpn J Clin Oncol 49:1055–1060. https://doi.org/10.1093/jjco/hyz112
同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3